GLP-1 and Exendin-4 Transiently Enhance GABAA Receptor–Mediated Synaptic and Tonic Currents in Rat Hippocampal CA3 Pyramidal Neurons
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is a hormone that stimulates insulin secretion. Receptors for GLP-1 are also found in the brain, including the hippocampus, the center for memory and learning. Diabetes is a risk factor for decreased memory functions. We studied effects of GLP-1 and exendin-4, a GLP-1 receptor agonist, on γ-aminobutyric acid (GABA) signaling in hippocampal CA3 pyramidal neurons. GABA is the main inhibitory neurotransmitter and decreases neuronal excitability. GLP-1 (0.01–1 nmol/L) transiently enhanced synaptic and tonic currents, and the effects were blocked by exendin (9-39). Ten pmol/L GLP-1 increased both the spontaneous inhibitory postsynaptic current (sIPSC) amplitudes and frequency by a factor of 1.8. In 0.1, 1 nmol/L GLP-1 or 10, 50, or 100 nmol/L exendin-4, only the sIPSC frequency increased. The tonic current was enhanced by 0.01–1 nmol/L GLP-1 and by 0.5–100 nmol/L exendin-4. When action potentials were inhibited by tetrodotoxin (TTX), inhibitory postsynaptic currents decreased and currents were no longer potentiated by GLP-1 or exendin-4. In contrast, although the tonic current decreased in TTX, it was still enhanced by GLP-1 or exendin-4. The results demonstrate GLP-1 receptor regulation of hippocampal function and are consistent with GLP-1 receptor agonists enhancing GABAA signaling by pre- and postsynaptic mechanisms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although GLP-1R stimulation has been shown to modulate GABAergic signaling in the hippocampus and NTS (38–40), the effects of GLP-1R agonism on GABAergic synapses in the CeA and ILC, especially in the context of alcohol drinking, are unknown.”
From The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission (2023) · cites this paper as [38]
Citations
Cites
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371 · cited 7×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundMethodInfluentialThe three-dimensional organization of the hippocampal formation: A review of anatomical data
Amaral, D. G., & Witter, M. P. (1989) · Neuroscience · doi:10.1016/0306-4522(89)90424-7 · Cited by 2,180 · cited 1×
“Both the CA3 and the CA1 neurons have critical roles in hippocampal-dependent memory and learning processes (43).”
BackgroundVariations on an inhibitory theme: phasic and tonic activation of GABAA receptors
Farrant, M., & Nusser, Z. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1625 · Cited by 2,081 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodResultInfluentialPharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialThe role of β-arrestins in the termination and transduction of G-protein-coupled receptor signals
Luttrell, L. M., & Lefkowitz, R. J. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.3.455 · Cited by 1,122
Glucagon-like peptide-1 receptor is involved in learning and neuroprotection
During, M. J., Cao, L., Zuzga, D. S., Francis, J. S., Fitzsimons, H. L., Jiao, X., Bland, R. J., Klugmann, M., Banks, W. A., Drucker, D. J., et al. (2003) · Nature Medicine · doi:10.1038/nm919 · Cited by 851 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialTonically active GABAA receptors: modulating gain and maintaining the tone
Semyanov, A., Walker, M. C., Kullmann, D. M., & Silver, R. A. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.03.005 · Cited by 743 · cited 8×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodResultInfluentialMojsov, S., Heinrich, G., Wilson, I. B., Ravazzola, M., Orci, L., & Habener, J. F. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)67324-7 · Cited by 724
Biessels, G. J., Strachan, M. W. J., Visseren, F. L. J., Kappelle, L. J., & Whitmer, R. A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70088-3 · Cited by 551 · cited 1×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundRecruitment of functional GABAA receptors to postsynaptic domains by insulin
Wan, Q., Xiong, Z. G., Man, H. Y., Ackerley, C. A., Braunton, J., Lu, W. Y., Becker, L. E., MacDonald, J. F., & Wang, Y. T. (1997) · Nature · doi:10.1038/41792 · Cited by 537 · cited 8×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodResultInfluentialRichards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialStructural Evidence for Functional Domains in the Rat Hippocampus
Risold, P. Y., & Swanson, L. W. (1996) · Science · doi:10.1126/science.272.5267.1484 · Cited by 450 · cited 8×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialVilsbøll, T., Agersø, H., Krarup, T., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021053 · Cited by 444 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialMcClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.08.005 · Cited by 361 · cited 1×
“, exendin-4, liraglutide, are reported to be neuroprotective and possible rescue cognition in models of Alzheimer, Parkinson, and Huntington disease (7,51).”
BackgroundBai, D., Zhu, G., Pennefather, P., Jackson, M. F., MacDonald, J. F., & Orser, B. A. (2001) · Molecular Pharmacology · doi:10.1124/mol.59.4.814 · Cited by 358 · cited 5×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialJin, S. ‐. C., Han, V. K. M., Simmons, J. G., Towle, A. C., Lauder, J. M., & Lund, P. K. (1988) · Journal of Comparative Neurology · doi:10.1002/cne.902710405 · Cited by 335 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialDynamic Equilibrium of Neurotransmitter Transporters: Not Just for Reuptake Anymore
Richerson, G. B., & Wu, Y. (2003) · Journal of Neurophysiology · doi:10.1152/jn.00317.2003 · Cited by 291
Abbas, T., Faivre, E., & Hölscher, C. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2009.06.035 · Cited by 282 · cited 1×
“GLP-1 has previously been shown to decrease glutamate-generated currents in cultured hippocampal neurons (48) and decrease hippocampal u wave duration in rats (30), and there is an impairment of synaptic plasticity and memory formation in GLP-1 receptor knockout mice (49).”
BackgroundLathe, R. (2001) · Journal of Endocrinology · doi:10.1677/joe.0.1690205 · Cited by 278 · cited 8×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundMethodInfluentialMultiple modes of GABAergic inhibition of rat cerebellar granule cells
Rossi, D. J., Hamann, M., & Attwell, D. (2003) · The Journal of Physiology · doi:10.1111/j.1469-7793.2003.00097.x · Cited by 256
Impaired insulin secretion increases the risk of Alzheimer disease
Rönnemaa, E., Zethelius, B., Sundelöf, J., Sundström, J., Degerman-Gunnarsson, M., Berne, C., Lannfelt, L., & Kilander, L. (2008) · Neurology · doi:10.1212/01.wnl.0000310646.32212.3a · Cited by 241
Target cell-specific modulation of neuronal activity by astrocytes
Kozlov, A. S., Angulo, M. C., Audinat, E., & Charpak, S. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603741103 · Cited by 235
Hamilton, A., & Hölscher, C. (2009) · NeuroReport · doi:10.1097/wnr.0b013e32832fbf14 · Cited by 227 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialMultiple modes of GABAergic inhibition of rat cerebellar granule cells
Rossi, D. J., Hamann, M., & Attwell, D. (2003) · The Journal of Physiology · doi:10.1113/jphysiol.2002.036459 · Cited by 217
Association of type 2 diabetes with brain atrophy and cognitive impairment
Roberts, R. O., Knopman, D. S., Przybelski, S. A., Mielke, M. M., Kantarci, K., Preboske, G. M., Senjem, M. L., Pankratz, V. S., Geda, Y. E., Boeve, B. F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000269 · Cited by 211 · cited 2×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundTuligenga, R. H., Dugravot, A., Tabák, A. G., Elbaz, A., Brunner, E. J., Kivimäki, M., & Singh-Manoux, A. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70192-x · Cited by 211 · cited 3×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundMcClean, P. L., Gault, V. A., Harriott, P., & Hölscher, C. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2009.12.023 · Cited by 193
A potential role for the hippocampus in energy intake and body weight regulation
Davidson, T. L., Kanoski, S. E., Schier, L. A., Clegg, D. J., & Benoit, S. C. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.008 · Cited by 178 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialInsulin inhibits pyramidal neurons in hippocampal slices
Palovcik, R. A., Phillips, M. I., Kappy, M. S., & Raizada, M. K. (1984) · Brain Research · doi:10.1016/0006-8993(84)91028-x · Cited by 174 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialIntranasal Insulin to Improve Memory Function in Humans
Benedict, C., Hallschmid, M., Schultes, B., Born, J., & Kern, W. (2007) · Neuroendocrinology · doi:10.1159/000106378 · Cited by 171
Duarte, A. I., Candeias, E., Correia, S. C., Santos, R. X., Carvalho, C., Cardoso, S., Plácido, A. I., Santos, M. S., Oliveira, C. R., & Moreira, P. I. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.01.008 · Cited by 162 · cited 3×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundIsacson, R., Nielsen, E. I., Dannaeus, K., Bertilsson, G., Patrone, C., Zachrisson, O., & Wikström, L. (2010) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2010.10.008 · Cited by 161 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialDiabetes drugs and neurological disorders: new views and therapeutic possibilities
Patrone, C., Eriksson, O., & Lindholm, D. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70125-6 · Cited by 161 · cited 2×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundReal-time trafficking and signaling of the glucagon-like peptide-1 receptor
Roed, S. N., Wismann, P., Underwood, C. R., Kulahin, N., Iversen, H., Cappelen, K. A., Schäffer, L., Lehtonen, J., Hecksher-Soerensen, J., Secher, A., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.11.010 · Cited by 153 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialWidmann, C., Dolci, W., & Thorens, B. (1995) · Biochemical Journal · doi:10.1042/bj3100203 · Cited by 152 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialQiu, C., Sigurdsson, S. O., Zhang, Q., Jónsdóttir, M. K., Kjartansson, Ó., Eiríksdóttir, G., Garcia, M. E., Harris, T. B., van Buchem, M. A., Gudnason, V. G., et al. (2013) · Annals of Neurology · doi:10.1002/ana.24063 · Cited by 151 · cited 1×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundGilman, C. P., Perry, T., Furukawa, K., Grieg, N. H., Egan, J. M., & Mattson, M. P. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02073.x · Cited by 125 · cited 1×
“GLP-1 has previously been shown to decrease glutamate-generated currents in cultured hippocampal neurons (48) and decrease hippocampal u wave duration in rats (30), and there is an impairment of synaptic plasticity and memory formation in GLP-1 receptor knockout mice (49).”
BackgroundTang‐Christensen, M., Vrang, N., & Larsen, P. J. (1998) · Diabetes · doi:10.2337/diabetes.47.4.530 · Cited by 125 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialStructural evidence for glucagon producing cells in the intestinal mucosa of the rat
Orci, L., PICTET, R. L., Forssmann, W. G., Renold, A. E., & Rouiller, C. (1968) · Diabetologia · doi:10.1007/bf01241034 · Cited by 124 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialMa, T., Du, X., Pick, J. E., Sui, G., Brownlee, M., & Klann, E. (2012) · Journal of Neuroscience · doi:10.1523/jneurosci.2107-12.2012 · Cited by 114 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialWidmann, C., Dolci, W., & Thorens, B. (1997) · Molecular Endocrinology · doi:10.1210/mend.11.8.9959 · Cited by 99 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialWidmann, C., Dolci, W., & Thorens, B. (1996) · Molecular Endocrinology · doi:10.1210/mend.10.1.8838146 · Cited by 82 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialInsulin Reduces Neuronal Excitability by Turning on GABAA Channels that Generate Tonic Current
Jin, Z., Jin, Y., Mendu, S. K., Degerman, E., Groop, L., & Birnir, B. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016188 · Cited by 81 · cited 8×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodResultSelf-citationDeuker, L., Doeller, C. F., Fell, J., & Axmacher, N. (2014) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2014.00064 · Cited by 71 · cited 8×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialZhou, X., Zhang, J., Chen, Y., Ma, T., Wang, Y., Wang, J., & Zhang, Z. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132354 · Cited by 64 · cited 1×
“Initially, the peptide GLP-1 (1-37) was identified from this processing, but later it was shown that there were two shorter peptides, GLP-1 (7-37) and GLP-1 (7-36)amide, that were the active species in vivo.”
BackgroundTask-Induced Brain Activity Patterns in Type 2 Diabetes: A Potential Biomarker for Cognitive Decline
Marder, T. J., Flores, V. L., Bolo, N. R., Hoogenboom, W. S., Simonson, D. C., Jacobson, A. M., Foote, S., Shenton, M. E., Sperling, R. A., & Musen, G. (2014) · Diabetes · doi:10.2337/db13-1783 · Cited by 59
Iwai, T., Suzuki, M., Kobayashi, K., Mori, K. J., Mogi, Y., & Oka, J. (2009) · Neuroscience Research · doi:10.1016/j.neures.2009.01.013 · Cited by 58 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialGlucagon-like peptide-1 modulates neuronal activity in the ratʼs hippocampus
Oka, J.-I., Goto, N., & Kameyama, T. (1999) · NeuroReport · doi:10.1097/00001756-199906030-00004 · Cited by 56 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialCerebrocortical Beta Activity in Overweight Humans Responds to Insulin Detemir
Tschritter, O., Hennige, A. M., Preissl, H., Porubska, K., Schäfer, S. A., Lutzenberger, W., Machicao, F., Birbaumer, N., Fritsche, A., & Häring, H.-U. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001196 · Cited by 53
Porter, D., Faivre, É., Flatt, P. R., Hölscher, C., & Gault, V. A. (2012) · Peptides · doi:10.1016/j.peptides.2012.03.014 · Cited by 53 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluentialCharacteristics of GABAA channels in rat dentate gyrus
Birnir, B., Everitt, A. B., & Gage, P. W. (1994) · The Journal of Membrane Biology · doi:10.1007/bf00233386 · Cited by 45 · cited 6×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodSelf-citationWidmann, C. (1996) · Molecular Endocrinology · doi:10.1210/me.10.1.62 · Cited by 42
Merchenthaler (1999) · doi:10.1002/(sici)1096-9861(19990111)403:2<261::aid-cne8>3.0.co;2-5 · cited 7×
“Exendin (9-39) (Ex9-39) is a competitive inhibitor of GLP-1 at the GLP-1 receptor (23).”
BackgroundMethodInfluential
Cited by
Is Alzheimer’s disease a type 3 diabetes? A critical appraisal
Kandimalla, R., Thirumala, V., & Reddy, P. H. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.08.018 · Cited by 621
“GABA receptors to postsynaptic membranes [29,30].”
Chuong, V., Farokhnia, M., Khom, S., Pince, C. L., Elvig, S. K., Vlkolinsky, R., Marchette, R. C. N., Koob, G. F., Roberto, M., Vendruscolo, L. F., et al. (2023) · JCI Insight · doi:10.1172/jci.insight.170671 · Cited by 214
“170671 field, showing increased GABAergic signaling in the hypothalamus (103) and hippocampus (38, 104, 105) of alcohol-naive rodents after treatment with GLP-1 or other GLP-1 analogues, which might be linked to increased intracellular cAMP levels after GLP-1R activation (39, 106, 107).”
Liu, J., Conde, K., Zhang, P., Lilascharoen, V., Xu, Z., Lim, B. K., Seeley, R. J., Zhu, J. J., Scott, M. M., & Pang, Z. P. (2017) · Neuron · doi:10.1016/j.neuron.2017.09.042 · Cited by 190
“…profound effects on synaptic transmission (for review see: Liu and Pang, 2016), however, the intracellular signaling cascades and pre- or postsynaptic site of action appear to be dependent on brain region and cell type (Acuna-Goycolea and van den Pol, 2004; Korol et al., 2015; Wang et al., 2015).”
Hamzé, R., Delangre, E., Tolu, S., Moreau, M., Janel, N., Bailbé, D., & Movassat, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315287 · Cited by 158
“Furthermore, insulin is implicated in the recruitment of the GABA (gamma-aminobutyric acid) receptor to the postsynaptic membrane, thus regulating inhibitory synapses [28,59,70,80,81].”
BackgroundGault, V. A., Lennox, R., & Flatt, P. R. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12432 · Cited by 141
“The precise mechanisms underlying the positive actions of GLP-1 receptor agonists on cognition are not yet known, but evidence points towards improved hippocampal synaptic plasticity and reduced GABAA receptor-mediated synaptic and tonic currents in CA3 pyramidal neurons [41,53].”
Metadata
- Authors
- Korol, S. V., Jin, Z., Babateen, O., & Birnir, B.
- Affiliations
- Uppsala University (SE)
- Corresponding author
- Birnir, Bryndis
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-08-11
- Volume
- 64
- Issue
- 1
- Pages
- 79-89
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2161146234
- Cited by
- 101
- References
- 52
- Citations by year
- 2026: 6 · 2025: 12 · 2024: 4 · 2023: 8 · 2022: 12 · 2021: 7 · 2020: 10 · 2019: 7 · 2018: 10 · 2017: 8 · 2016: 10 · 2015: 7
- FWCI
- 3.81
- Type
- journal article
- Language
- en
- Open access
- green
- urn.kb.se
- Licence
- other-oa
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Uppsala University Publications (Uppsala University) (submittedVersion, other-oa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Keywords
- glucagon-like peptide-1, exendin-4, GLP-1 receptor, GABAA receptor, hippocampal CA3 pyramidal neurons, inhibitory postsynaptic currents, tonic inhibition, GABA signaling, exendin-9-39, tetrodotoxin, synaptic inhibition
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, gamma-Aminobutyric Acid, Membrane Potentials, Memory, Synaptic Transmission, Organ Culture Techniques, Peptides, Receptors, GABA-A, Tetrodotoxin, Venoms, Signal Transduction, Rats, Wistar, Pyramidal Cells, Receptors, Glucagon, Patch-Clamp Techniques, Sodium Channel Blockers, Glucagon-Like Peptide 1, Inhibitory Postsynaptic Potentials, CA3 Region, Hippocampal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.